HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CPSC nomination

This article was originally published in The Rose Sheet

Executive Summary

President Bush announces intention to nominate Harold Stratton to chair the Consumer Product Safety Commission Oct. 30. Albuquerque lawyer is "known consumer advocate" who served as Attorney General of New Mexico from 1987-1990 and was a member of New Mexico House of Representatives from 1979-1986, according to a White House spokesperson. Stratton currently is a partner with the law firm Stratton & Cavin (Albuquerque). Senate confirmation is required for the CPSC role; no hearings have yet been scheduled. The Bush Administration abandoned its push to appoint Mary Sheila Gall as chair after her nomination was defeated by Senate Democrats (1"The Rose Sheet" Aug. 6, In Brief)..

You may also be interested in...



CPSC leadership

Nomination of Harold Stratton to chair Consumer Product Safety Commission, take over as commissioner for remainder of term expiring Oct. 26, 2006, sent to the Senate March 13. Nomination will go before the Commerce Committee; no confirmation hearings have been scheduled. Bush Administration announced its choice in November, after Mary Sheila Gall's nomination was defeated by Senate Democrats (1"The Rose Sheet" Nov. 5, 2001, In Brief)...

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel